Promising Pathways t
Promising Pathways to Simplified Alzheimer's Diagnosis Unveiled in Groundbreaking Study
February 28, 2024 07:00 ET | Global Alzheimer’s Platform Foundation®
Washington D.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Washington D.C., Feb. 28, 2024- The Global Alzheimer’s Platform Foundation®, (GAP) is releasing the first results from the Bio-Hermes-001 Study....
Blue California successfully completes groundbreaking human clinical trial of ergothioneine.
Blue California completes groundbreaking human clinical trial on ErgoActive® ergothioneine intervention for cognitive function, memory, and sleep
February 05, 2024 04:00 ET | Blue California Ingredients
Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Blue California, an industry leader in science-driven ingredient development, announced the successful completion of a...
AMVETS
NC AMVETS Service Foundation Launches CBD Study for Veterans with University of Northern Colorado and Vantage Hemp Co.
January 31, 2024 07:00 ET | NC AMVETS Service Foundation
Rockwell, North Carolina, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The North Carolina AMVETS Service Foundation, a 501(c)(3) extension of the state’s most inclusive congressionally chartered veterans...
InflaRx on large white.jpg
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
January 04, 2024 07:00 ET | InflaRx N.V.
MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days: Achieved ≥90%...
Stacked logo.png
Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia
October 31, 2023 03:00 ET | Sosei Group Corporation
NDA includes robust data from a Phase 3 trial that demonstrated efficacy of daridorexant on improving Total Sleep Time and Latency for Sleep Onset, while maintaining a favorable safety profileSosei...
Clinical ink Introdu
Clinical ink Introduces Breakthrough Solution to Drastically Reduce Study Build Timelines
October 12, 2023 06:00 ET | Clinical Ink
Winston Salem, NC, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, is setting a new industry benchmark in advancing study build timelines. Harnessing the...
Logo.png
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus
September 28, 2023 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces dosing of the first subjects in a Phase 1 clinical trial with its...
Logo 400x400.jpg
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
September 27, 2023 07:00 ET | CytoSorbents
CytoSorbents summarizes real-world data from STAR Registry analysis being presented next week at European Association of Cardio-Thoracic Surgery Congress
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA® (pembrolizumab)
September 19, 2023 04:00 ET | AKAMPION
YONGIN, South Korea, September 19, 2023 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative...
adrenomed-logo (002).jpg
Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update
September 08, 2023 04:00 ET | Adrenomed AG
Patient population benefitting most from enibarcimab treatment in septic shock can clearly be defined by two biomarkers, as shown by data presented todayIn the AdrenOSS-2 trial, the respective patient...